TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Liver fat change after three weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of 2-hours glucose levels in mixed meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of insulin concentration (mIU/ml) in mixed-meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cost per beneficiary per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Thalamic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Prostate Volume measured by transrectal ultrasound (TRUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Objective Tumor Response (RECIST 1.0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Colorectal Cancer Screening Rates - Initial FIT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Colorectal Cancer Screening Rates - Repeat FIT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: RNFL and GCC thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: patients satisfaction with anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive Capacity for children between 7 and 10 years of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Capacity for children between 4 and 7 years of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Capacity for children between 2 and 4 years of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with Dose Limiting Toxicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in prostate-specific antigen from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of adverse events requiring a higher level of care
Endpoint domain: Adverse events/effects
Primary endpoint: The number of participants with preventable adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: burden of hypoxemia on regional cerebral saturation (rStO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with tactile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score of gross manual dexterity assessment test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score of hand grip strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation and distribution of different endophenotypes (Neuropattern)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of desmosine and isodesmosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eicosanoid Metabolites Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % responder to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: control the systemic manifestations of SJIA such as fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant Engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recurrence of back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Postprandial Area Under the Curve (AUC[0-8]) for Active Glucagon-like Peptide-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients with Ca x P product lower than 55
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of patients with remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial dependent dilatation of the arterial wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-Müllerian hormone (AMH) serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fever defined as oral temperature ≥101°F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinically Significant Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (0-t) of Melphalan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity in detecting stenosis (>50% occlusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Indicators of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of elevated pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of elevated vasomotor reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum ankle MRI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decision Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma concentration of prothrombin fragment 1+2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentration of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum concentration of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain measured on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in life quality measured with the DLQI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Isometric Maximal Voluntary Contraction (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counter Movement Jump (CMJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16.1 Kilometer (km) Cycling Time Trial (TT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of intracranial tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetics of Daptomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes Per Week of Moderate to Vigorous Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Modified Fatigue Impact Scale (MFIS) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Parent Relationship Questionnaire 2-5 (PRQ2-5) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in HOME Infant / Toddler / Early Childhood Record Form scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Symptom Checklist 90 Revised (SCL-90 R) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Psychological Well-Being Scales scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants surviving at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants surviving at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants surviving at 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of COVID-19 cases after two doses of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of COVID-19 cases after the booster dose of immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 4beta-OHcholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under The Plasma Concentration-time Curve From 0 to t Hours Postdosing (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Bioavailability (F[rel])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staging and ReStaging scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sensitivity of post processing method for classification of psychogenic nonepileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of disease development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of intervention delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total numbers of acne reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Patients With At Least One Adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gut-derived glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Length of stay in the secure forensic hospital setting
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Recovery from psychosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in violence
Endpoint domain: Adverse events/effects
Primary endpoint: plasma drug concentration of conivaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: knee joint muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ankle joint muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plantar contact during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's global assessment of tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Exercise Treadmill Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IDH mutation status in brain cancer participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Primary, primary-assisted and secondary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: postoperative complication status
Endpoint domain: Adverse events/effects
Primary endpoint: early period complication status
Endpoint domain: Adverse events/effects
Primary endpoint: late period complication status
Endpoint domain: Adverse events/effects
Primary endpoint: early recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: late recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Measured Liver Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Without Fracture Displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Annualized Rate of Change in MeanMax CIMT Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of assays developed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the plasma concentration of ME1111
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Subjects Achieving ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Urinary Incontinence Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Cases Per Month of New Cases of HIV and Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean Cases Per Month of Existing Cases of HIV and Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Event (AE) monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: functional neural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of ILC2 and tuft cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Passive and active extension deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dimension of palpable nodules and cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal diameter of the proximal ascending aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Schirmer's I test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Ulcer Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in distance best spectacle corrected visual acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in seizure frequency/severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Exercise Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Develop Skin Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Skin Rash Stratified by Severity Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Identification rate of Inked nodes containing seed and clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Identification rate of Inked nodes not containing seed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Identification rate of Inked nodes not containing clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Identification rate of Inked nodes not containing seed or clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Shearwave Elastography measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Beta Band Power (13-30 Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UPDRS III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Capacity - 6-minute walk test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Care Capacity - Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knowledge of Risk Factors - Evaluation of knowledge regarding alarm signs and cardiovascular risk factors
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SCL-20 depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volume change of bony fusion mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient-rated Quality-of-Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Plasma Glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With HBV DNA >= 50 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnosis of true severe AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of leukemic child patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metastasis rate of lateral lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline in fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Dysmorphic Disorder Modification of the Y-BOCS (BDD-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Model for End Stage Liver Disease (MELD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion of Free Flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in intestinal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death due to DVT/PE
Endpoint domain: Mortality/survival
Primary endpoint: Failures of resolution, extension or recurrence of DVT and/or PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of major haemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: Inconvenience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper Extremity Fugl-Meyer Motor Function Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible index clients offered VAPN services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: laboratory blood and urine tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Annual progression of arterial rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial perfusion quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: biodistribution of fluoromethane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temperature Rise from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Counts Above 50,000/ul
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Feasibility of exergames
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in insulin-resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in inflammatory response to E. coli endotoxin injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of detected atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of regenerative-treated tooth loss after periodontal regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of regenerative-treated sites with clinical attachment loss ≥ 2 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spirometry with reversibility results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 9-month Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Methylation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in outcome data in PIDD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ibudilast and temozolomide combination treatment
Endpoint domain: Adverse events/effects